Tankyrase-tankyrase.com

Additional information:
Aminooxy-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.{{Spartalizumab} medchemexpress|{Spartalizumab} Immunology/Inflammation|{Spartalizumab} Biological Activity|{Spartalizumab} Description|{Spartalizumab} supplier|{Spartalizumab} Epigenetic Reader Domain} Aminooxy-PEG2-azide is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).PMID:32727246 |Product information|CAS Number: 1043426-13-6|Molecular Weight: 190.20|Formula: C6H14N4O3|Chemical Name: O-{2-[2-(2-azidoethoxy)ethoxy]ethyl}hydroxylamine|Smiles: [N-]=[N+]=NCCOCCOCCON|InChiKey: GCURLNTZWQFVMK-UHFFFAOYSA-N|InChi: InChI=1S/C6H14N4O3/c7-10-9-1-2-11-3-4-12-5-6-13-8/h1-6,8H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.|Products are for research use only. Not for human use.|

Additional information:
Hydroxy-Amino-bis(PEG2-propargyl) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.|Product information|CAS Number: 2100306-77-0|Molecular Weight: 313.39|Formula: C16H27NO5|Chemical Name: 2-(4,7,13,16-tetraoxa-10-azanonadeca-1,18-diyn-10-yl)ethan-1-ol|Smiles: C#CCOCCOCCN(CCO)CCOCCOCC#C|InChiKey: CFAWPKGCJLYIOW-UHFFFAOYSA-N|InChi: InChI=1S/C16H27NO5/c1-3-9-19-13-15-21-11-6-17(5-8-18)7-12-22-16-14-20-10-4-2/h1-2,18H,5-16H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Abietic acid} site|{Abietic acid} Anti-infection|{Abietic acid} Purity & Documentation|{Abietic acid} In Vitro|{Abietic acid} custom synthesis|{Abietic acid} Autophagy} |Shelf Life: ≥12 months if stored properly.{{Varenicline} web|{Varenicline} Neuronal Signaling|{Varenicline} Protocol|{Varenicline} Description|{Varenicline} custom synthesis|{Varenicline} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:31869128 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.|Products are for research use only. Not for human use.|

Additional information:
Hematoporphyrin monomethyl ether, second generation of porphyrin-related photosensitizer, is characterized by its single form, high yield of singlet oxygen, high selectivity, and low toxicity, which has been widely used in the diagnosis and treatment of various tumors, including lung cancer, bladder cancer, and nevus flammeus and brain glioma.PMID:32967527 |Product information|CAS Number: 148471-91-4|Molecular Weight: 612.72|Formula: C35H40N4O6|Chemical Name: 3-[20-(2-carboxyethyl)-14-(1-hydroxyethyl)-9-(1-methoxyethyl)-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶]tetracosa-1,3(24),4,6,8,10,12,14,16,18(21),19-undecaen-4-yl]propanoic acid|Smiles: CC(O)C1C2=CC3NC(C=C4N=C(C=C5N=C(C=C(N2)C=1C)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C4C)=C(C(C)OC)C=3C|InChiKey: NDYWLKUTUDKOAS-OYYVZGGRSA-N|InChi: InChI=1S/C35H40N4O6/c1-16-22(8-10-32(41)42)28-15-29-23(9-11-33(43)44)17(2)25(37-29)13-31-35(21(6)45-7)19(4)27(39-31)14-30-34(20(5)40)18(3)26(38-30)12-24(16)36-28/h12-15,20-21,38-40H,8-11H2,1-7H3,(H,41,42)(H,43,44)/b24-12-,25-13-,26-12-,27-14-,28-15-,29-15-,30-14-,31-13-|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Hematoporphyrin monomethyl ether (HMME) is a novel and promising porphyrin-related photosensitizer for photodynamic therapy (PDT). HMME-PDT can induce cell deaththrough both necrosis and apoptosis in HeLa cells. ROS, such as singlet oxygen and hydroxyl radical, generated in HeLa cells play a decisive role in HMME-PDT-induced cell death.|Products are for research use only. Not for human use.|

Additional information:
Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.|Product information|CAS Number: 1698878-14-6|Molecular Weight: 419.49|Formula: C20H25N3O5S|Chemical Name: 2-hydroxy-2-methyl-N-{2-[2-(pyridin-3-yloxy)acetyl]-1,2,3,4-tetrahydroisoquinolin-6-yl}propane-1-sulfonamide|Smiles: CC(C)(O)CS(=O)(=O)NC1=CC2CCN(CC=2C=C1)C(=O)COC1C=NC=CC=1|InChiKey: QHHSCLARESIWBH-UHFFFAOYSA-N|InChi: InChI=1S/C20H25N3O5S/c1-20(2,25)14-29(26,27)22-17-6-5-16-12-23(9-7-15(16)10-17)19(24)13-28-18-4-3-8-21-11-18/h3-6,8,10-11,22,25H,7,9,12-14H2,1-2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (595.{{Nomegestrol} MedChemExpress|{Nomegestrol} Vitamin D Related/Nuclear Receptor|{Nomegestrol} Purity & Documentation|{Nomegestrol} Data Sheet|{Nomegestrol} manufacturer|{Nomegestrol} Autophagy} 96 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|To assess its selectivity, specificity, and effects on cellular NAD+ levels, LSN3154567 is characterized in various biochemical and cellular assays.{{Amiloride hydrochloride dihydrate} MedChemExpress|{Amiloride hydrochloride dihydrate} Inhibitor|{Amiloride hydrochloride dihydrate} TGF-beta/Smad|{Amiloride hydrochloride dihydrate} Protocol|{Amiloride hydrochloride dihydrate} In Vitro|{Amiloride hydrochloride dihydrate} supplier} LSN3154567 inhibits purified NAMPT with an IC50 of 3.1 nM. When tested against a panel of human kinases (>100; CEREP Kinase panel), it does not exhibit any significant activity (i.e.: IC50≥1 μM) against the kinases tested except CSF1R (IC50≈0.84 μM). LSN3154567 exhibits a broad spectrum of anticancer activity. To assess its anticancer activity, LSN3154567 is tested against a number of different types of cancer cell lines cultured in the absence or presence of nicotinic acid (NA) (10 μM).PMID:31916914 LSN3154567 exhibits a potent antiproliferative activity against many cell lines in the absence of NA.|In Vivo:|Nampt-IN-1 (LSN3154567) exhibits good physical chemical properties that allow oral dosing. When dosed orally with 2 mg/kg in mice, it has an exposure of 195 nM*hour in the plasma with a peak concentration of 57 nM (at 0.25 hour) and an oral bioavailability of 39%. When dosed intravenously with 2 mg/kg, it has a hepatic clearance of 158.73 mL/min/kg and a volume of distribution at 7.1 L/kg. The half-life of terminal elimination is estimated to be 2.76 hours. LSN3154567 exhibits a dose-dependent inhibition of NAD+ formation with estimated TED50 value of 2.0 mg/kg. To assess whether LSN3154567 causes retinopathy, rats are treated with LSN3154567 at 20, 40, and 80 mg/kg for 4 days. No apparent retinopathy is observed. The hematological toxicities are observed. When LSN3154567 is dosed at 20, 40, and 80 mg/kg, the plasma exposures obtained are 8,974, 18,061, and 38,327 M*h, respectively. Thus, LSN3154567 exhibits exposure multiples of respective 3-, 7-, and 14-fold over the exposure (2,701 M*h) required for robust efficacy (≈103%) without NA coadministration. Dogs are treated with LSN3154567 at 1 and 2.5 mg/kg. At these dose levels, the retinal toxicity is observed. Degeneration of the outer nuclear layer occurred in all four animals, but is less pronounced in the animals treated with 1 mg/kg. At the 1 and 2.5 mg/kg dose levels, the plasma exposures are determined to be 1,483 and 2,468 nM*h, respectively.|Products are for research use only. Not for human use.|

Additional information:
Ms-PEG8-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.{{Abatacept} site|{Abatacept} CTLA-4|{Abatacept} Purity & Documentation|{Abatacept} In stock|{Abatacept} supplier|{Abatacept} Epigenetics} |Product information|CAS Number: 2097604-01-6|Molecular Weight: 576.PMID:32589561 70|Formula: C24H48O13S|Chemical Name: tert-butyl 1-(methanesulfonyloxy)-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oate|Smiles: CC(C)(C)OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOS(C)(=O)=O|InChiKey: ARFPSYCSFDJABG-UHFFFAOYSA-N|InChi: InChI=1S/C24H48O13S/c1-24(2,3)37-23(25)5-6-28-7-8-29-9-10-30-11-12-31-13-14-32-15-16-33-17-18-34-19-20-35-21-22-36-38(4,26)27/h5-22H2,1-4H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.|Products are for research use only. Not for human use.|